Mens Health Erection Articles

Men with spinal cord injuries appear to have better erectile function when they take tadalafil, according to a report published in Archives of Neurology (JAMA/Archives), November 2007 issue.
Spinal cord injuries are much more common than many people realize; globally about 10.4 to 83 people per million are affected by spinal cord injuries annually, say the authors. "Kaufen viagra pillen mastercard Throughout the world, spinal cord injury occurs most often in young men, resulting in negative physical, social and psychological consequences. Erectile dysfunction, defined as the inability to attain and maintain penile erection sufficient for satisfactory sexual performance, is a common complication in men with spinal cord injury."
The authors point out that only about one quarter of men with spinal cord injuries manage to have an erection adequate for having sexual intercourse.
Francois Giuliano, M.D., Ph.D., Raymond Poincare Hospital, Garches, France, and team, carried out a randomized, double-blind study on 197 men with spinal cord injuries; their average age was 38. First of all they were all monitored, without treatment for erectile dysfunction. Then 142 of them were randomly selected to receive tadalafil, while 44 received a placebo. The treatment lasted 12-weeks - the participants were asked to take their medication whenever they needed it; before sexual activity, maximum dose one per day. The tadalafil group were given a 10-milligram dose initially, and then 20-milligrams four weeks later, depending on their response to the initial treatment.
The researchers used the International Index of Erectile Function questionnaire. It consists of 15 questions; if a person scores lower than 25 he is deemed as someone who suffers from varying degrees of erectile dysfunction. At the beginning of the study the participants’ average score was 13.4. At the end of the twelve week period the average score for the tadalafil group went up to 22.6. The placebo group’s score rose slightly to 13.6.
Those on tadalafil managed to successfully achieve penetration 75.4% of the time, while successfully attempting intercourse for 47.6% of the time. The participants on the placebo managed to successfully achieve penetration 41.1% of the time while successfully attempting intercourse for 16.8% of the time.
The researchers wrote "Tadalafil was safe and well tolerated with few treatment-emergent side effects," the authors write. Fifty (35%) of patients in the tadalafil group and 15 (34%) of those in the placebo group experienced at least one adverse effect. Among those taking tadalafil, the most common side effects were headache (8.5% of patients) and urinary tract infection (7.7% of patients). As in other erectile dysfunction studies that include patients who were difficult to treat owing to pre-existing conditions (e.g., prostatectomy, diabetes mellitus), tadalafil was efficacious for the treatment of erectile dysfunction after a traumatic spinal cord injury," the authors write. "On-demand treatment with tadalafil (10 milligrams or 20 milligrams) may help improve the sex lives of patients with erectile dysfunction and spinal cord injury and their partners."
"Efficacy and Safety of Tadalafil in Men With Erectile Dysfunction Following Spinal Cord Injury"
Fran?§ois Giuliano, MD, PhD; Antonio Sanchez-Ramos, MD; Dieter L?¶chner-Ernst, MD; Giulio Del Popolo, MD; Natalio Cruz, MD; Albert Leriche, MD; Giuseppe Lombardi, MD; Susanne Reichert, MD; Palle Dahl, MSc; Albert Elion-Mboussa, MS; Joaquin Casariego, MD
Arch Neurol. 2007;64:(doi:10.1001/archneur.64.11.nct70001).
Click here to view abstract and article online
Written by: Christian Nordqvist
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
Kaufen generishe cialis soft | Kaufen generishe viagra | generishe viagra soft pillen Ohne Rezept

NexMed, Inc. (Nasdaq: NEXM), a developer of innovative transdermal products based on its proprietary NexACT® drug delivery technology, announced that the New Drug Application (NDA) filed by the Company for its erectile dysfunction (ED) product, a topically applied alprostadil cream, was accepted for review by the U.S. Food and Drug Administration (FDA).
"We are pleased to announce the FDA’s acceptance of our submission for our ED product," stated Vivian Liu, President and Chief Executive Officer of NexMed. "generishe cialis online kaufen mastercard We have already begun working with the agency and with our partner, Warner Chilcott, and look forward to gaining regulatory approval for this important new therapy. I am confident in Warner Chilcott’s CEO Roger Boissonneault and his team’s ability to establish a major presence in urology. With their proven success in building new markets, Warner Chilcott is a great partner for launching this product, upon its approval."
The acceptance for review is an indication that the FDA has determined that the filing is sufficient to complete a substantive review of the application, which customarily takes a minimum of eight months, should the FDA not require any additional studies or information.
About NexMed
NexMed, Inc. is leveraging its proprietary NexACT® drug delivery technology to develop innovative topical pharmaceutical products that address unmet medical needs. NexMed’s novel, onychomycosis treatment, licensed to Novartis, is currently in pivotal Phase 3 trials in the U.S. and Europe. NexMed’s pipeline also includes a Phase 2 treatment for female sexual arousal disorder and an early stage treatment for psoriasis. For further information about the Company, go to
Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to whether and when the FDA will approve the Company’s ED Product.
NexMed
Kaufen cialis pillen mastercard | generishe viagra soft online kaufen mastercard | kaufen cialis soft Ohne Rezept

While penile prosthesis devices are the most invasive and least chosen treatments for erectile dysfunction (ED), the devices garner the highest patient satisfaction rates. In the April 2008 issue of Urologic Nursing, Annette Liechty and Susanne A. Quallich review a teaching process that nurses can use to show a patient to successfully operate the device.
Liechty and Quallich say the single most important aspect of teaching patients to use their penile prosthesis is ensuring the patient is comfortable with and physically able to operate the device. Patients are generally very motivated to operate the device, say the authors, as it allows for spontaneity in sexual relationships, unavailable before the prosthesis surgery.
The authors acknowledge adults learn in different ways and encourage health care providers to use an appropriate style (verbal, written or demonstration) when teaching patients to use the device. Kaufen generishe cialis Liechty and Quallich say addressing these issues in a compassionate and professional manner can help patients achieve a satisfactory degree of sexual functioning.
"Teaching a Patient to Successfully Operate a Penile Prosthesis"
Annette Liechty, LPN, CUA; Susanne A. Quallich, APRN, BC, NP-C, CUNP
Urologic Nursing; April 2008; www.suna.org
About SUNA (Society of Urologic Nurses and Associates)
The Society of Urologic Nurses and Associates is a national, non-profit professional membership association with over 3,000 members and annual revenues of $1.5 million. SUNA derives its income from membership dues ($60), conference registration fees, exhibits, advertising, grants, and the sale of educational products.
SUNA publishes a professional, peer-reviewed bi-monthly journal (Urologic Nursing Journal) and a bi-monthly newsletter (Uro-Gram). SUNA establishes the scope and standards of urologic nursing practice and the scope and standards of advanced urologic nursing practice. SUNA provides scholarships, grants and awards to deserving nurses and other health care professionals. SUNA supports and promotes the certification of urologic nurses and associates by providing educational preparation for the examinations offered which lead to certification in three areas. SUNA provides a variety of opportunities for participation including local chapters, task forces and Special Interest Groups (SIGS) in five major subspecialty areas.
www.suna.org
kaufen levitra Ohne Rezept | Kaufen generishe cialis | generishe cialis soft online kaufen mastercard

Latest News For This Category
Correlation Between Erectile Dysfunction And LUTS The AUA Lecture
19 Apr 2008
A Mixed Set Of Results From 5-Alpha-Reductase Inhibitors And Reduced Prostate Cancer Risk
16 Apr 2008
Federal Authorities Seize More Than 100,000 Dollars Of Unapproved Drugs Marketed As "Natural Supplements"
10 Apr 2008
View more news…
Latest Videos for Erectile Dysfunction
Penile Pump Expectations
comprare il viagra soft pillole|comprare generico viagra soft|generico viagra soft in linea comrare|comprare il viagra soft senza ricetta|Generico viagra soft pillole senza ricetta For many men suffering from erectile dysfunction, the solution to their problem lies not in medications or sex therapy but rather in a surgically implanted device called an Internal Penile Pump…
Penile Pump Implants
Since its invention, the internal penile pump has helped over 250,000 men suffering from erectile dysfunction. Choosing this option is a major decision and many are concerned about its long-term effects. Join our panel of doctors, patients and a partner as they share their post-operation…
View more videos…
Advertisements
Add Your Advertisement Here
Most Read Articles From The Last 7 Days
Vitamin Supplements Don’t Help You Live Longer, Study
16 Apr 2008
Life Expectancy Disparities Increasing In The US
22 Apr 2008
Diet Designed To Lower Blood Pressure May Also Fight Heart Disease And Stroke
16 Apr 2008
Polycarbonate Baby Bottles Containing Bisphenol A May Become Banned In Canada
19 Apr 2008
Baby’s Gender Linked To Mother’s Diet At Conception
23 Apr 2008
Most Popular Categories
public health
neurology
nutrition
cancer
cardiovascular
hiv
diabetes
dermatology
obesity
alcohol
psychology
women’s health
infectious diseases
pediatrics
breast cancer
urology
pregnancy
gastrointestinal
pain
respiratory
prostate
bones
depression
smoking
medical devices
health insurance
medicare
hypertension
stem cell research
biology
alzheimer’s
sexual health
sleep
abortion
genetics
allergy
autism
eye health
adhd
it
multiple sclerosis
sports medicine
pharma industry
dentistry
liver disease
anxiety
arthritis
seniors
cholesterol
mrsa
comprare il cialis soft pillole|comprare generico cialis soft|generico cialis soft in linea comrare|comprare il cialis soft senza ricetta|Generico cialis soft pillole senza ricetta | comprare il levitra pillole|comprare generico levitra|generico levitra in linea comrare|comprare il levitra senza ricetta|Generico levitra pillole senza ricetta | comprare il viagra soft pillole|comprare generico viagra soft|generico viagra soft in linea comrare|comprare il viagra soft senza ricetta|Generico viagra soft pillole senza ricetta

Men’s Health News
Even though deaths from prostate cancer death have fallen in the U.S. since screening became more common, new research is suggesting that this does not justify the need for such tests.
According to a team of scientists from the University of Bristol many other factors could be involved such as different treatment programmes for American men and some discrepancy over how deaths are reported.
Since screening became widespread in the U.S. mortality rates have fallen four times more than in the UK.
It seems that many men over 80 have evidence of prostate cancer when they die, but it is often unclear whether this or other conditions killed them, which leads to different accounts on death certificates.
The researchers say this does not mean that screening by using a blood test to detect what is known as the prostate specific antigen (PSA), is not saving lives.
But they suggest until research pins down the exact role of screening in decreasing prostate cancer mortality, it remains a matter of speculation.
Whereas prostate cancer screening became common in the States in the early 1990s, and nearly 60% of men over 50 were being tested by 2001, in the UK, between 1999 and 2002, an estimated 6% of men aged 45-84 had been tested.
At the start of the 90s, mortality rates for the two countries were similar, but after this period, the rate of decline in the U.S. at 4.17% per year, was almost four times that of the UK, at 1.17% per year.
Simon Collin a statistician who led the research says other changes were occurring in the treatment of men with prostate cancer in the U.S. during that time and included the use of a particular hormone treatment in older men and more aggressive treatment of those with an advanced form of the disease.
Prostate cancer accounts for a quarter of cancers in men but the National Health Service (NHS) has resisted offering widespread PSA screening because the test is seen as notoriously inaccurate.
Even though 10-15% of men will have high enough PSA levels to justify carrying out a prostate biopsy, only 2-3% will require any treatment.
This means in fact that the majority will have been subjected to unpleasant, invasive and potentially costly investigations for no reason with possible serious side effects such as impotence and incontinence.
Experts say there is an urgent need for a new diagnostic test which could form part of a national screening programme and which would reliably identify the aggressive prostate cancers that need treatment.
Buy diflucan without prescription The NHS says all screening programmes are based on an assessment that more good than harm will be achieved through their implementation and until there is clear clinical evidence to show real benefit can be gained from routine prostate screening, the NHS will not be screening men who have no symptoms for prostate cancer.
The authors of the study say while the differing outcomes are worrying, the jury is still out on whether screening is worthwhile.
The research is published in Lancet Oncology.
Buy clomid without prescription | Buy lexapro without prescription | Buy fosamax pills